Diasome Pharmaceuticals to Present at the 68th Annual American Diabetes Association...

Diasome Pharmaceuticals to Present at the 68th Annual American Diabetes Association Meeting

CONSHOHOCKEN, Pa.--(Business Wire)--
Diasome Pharmaceuticals, a clinical stage diabetes therapeutics
company, announced today that four abstracts were accepted for
publication at the 68th Annual Meeting of the American Diabetes
Association, being held June 6 through June 10 at the Moscone
Convention Center in San Francisco, Ca.

All of the abstracts highlight HDV-Insulin, the Company's
proprietary oral and injectable insulin products. The following will
be presented as posters from Saturday, June 7 through Monday, June 9
in Hall D:

-- A 2-Week Randomized Active Comparator Study of Two HDV-Insulin
Routes (SC and Oral) and SC Human Insulin in Patients with
Type 1 Diabetes Mellitus. Sherwyn Schwartz, MD, Blair Geho,
MD, PhD, Len Rosenberg, PhD, RPh, John Lau. Diabetes and
Glandular Research Center, San Antonio, TX, and Diasome
Pharmaceuticals, Conshohocken, PA.

-- Single-Blind, Placebo-Controlled, Dose-Ranging Trial of Oral
HDV-Insulin in Patients with Type 2 Diabetes Mellitus. Sherwyn
Schwartz, MD, Blair Geho, MD, PhD, Len Rosenberg, PhD, RPh,
John Lau. Diabetes and Glandular Research Center, San Antonio,
TX, and Diasome Pharmaceuticals, Conshohocken, PA.

-- Hepatic-Directed Vesicle Insulin: Evaluation of a Novel Oral
and Subcutaneous Insulin Delivery System in Animal Models of
Diabetes. Blair Geho, MD, PhD, John Lau, Len Rosenberg, PhD,
RPh, Diasome Pharmaceuticals, Conshohocken, PA.

In addition, presenters will be on hand Saturday, June 7, from
11:30 a.m. to 1:30 p.m., and on Monday, June 9, from noon to 2 p.m.
for questions and discussions with attendees.

Diasome is developing Oral HDV-Insulin, a nanotechnology-based
cell targeting system for the improved treatment of diabetes mellitus.
Diasome's therapies have been tested in more than 100 subjects to
date. The Company is preparing to conduct longer term clinical trials
in 2008 after having held an end of Phase II meeting with the FDA in
2007.

About Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals, Inc. is a venture-backed
biopharmaceutical company focused on novel insulin-based therapies for
the improved treatment of diabetes. The Company was formed in 2004 and
has completed multiple Phase II human studies of HDV-Insulin, its
proprietary insulin targeting system. Diasome uses a unique,
nano-technology based cell targeting system to preferentially deliver
insulin to the hepatocytes in the liver. This technology has led to
the development of Oral HDV-Insulin, an advanced oral delivery system
for insulin. For more information, please visit Diasome's website at
www.Diasome.com.

About the American Diabetes Association

The American Diabetes Association (ADA) is the nation's premier
voluntary health organization supporting diabetes research,
information and advocacy. Founded in 1940, the Association's mission
is to prevent and cure diabetes and to improve the lives of all people
affected by diabetes. The Association's commitment to research is
reflected through its scientific meetings; education and provider
recognition programs; and its Research Foundation and Nationwide
Research Program, which fund breakthrough studies looking into the
cure, prevention, and treatment of diabetes and its complications.
www.Diabetes.org

Gregory FCA
Theresa Murray, 610-642-8253 x164
Theresa@GregoryFCA.com

Copyright Business Wire 2008